Parameters | CHB group (n = 32) | Non-CHB group (n = 128) | p valuea |
---|---|---|---|
Matched parameters | |||
 Female, n (%) | 27 (84) | 108 (84) | 1.000 |
 Age (years) | 49 (38–56) | 49 (38–57) | 0.964 |
 DAS28-CRP | 4.6 (3.5–5.0) | 4.6 (3.8–5.3) | 0.791 |
Demographic characteristics | |||
 Age of onset (years) | 44 (31–52) | 45 (33–53) | 0.948 |
 Disease duration (months) | 36 (9–113) | 36 (12–84) | 0.805 |
  Short duration (<6 months) | 3 (9) | 19 (15) | 0.476 |
  Intermediate duration (6–24 months) | 12 (38) | 39 (30) | 0.501 |
  Long duration (>24 months) | 17 (53) | 70 (55) | 0.887 |
Disease characteristics | |||
 TJC28 | 6 (2–10) | 6 (3–10) | 0.914 |
 SJC28 | 4 (1–8) | 4 (2–6) | 0.523 |
 PainVAS | 4 (2–5) | 4 (3–6) | 0.131 |
 PtGA | 5 (3–6) | 5 (3–6) | 0.355 |
 PrGA | 5 (3–5) | 5 (3–6) | 0.276 |
 HAQ | 0.6 (0–1.3) | 0.6(0.1–1.2) | 0.888 |
 CRP (mg/L) | 12.1 (3.8–44.2) | 12.1 (4.8–32.0) | 0.543 |
 ESR (mm/h) | 36 (20–62) | 50 (24–75) | 0.162 |
 RF positivity, n (%) | 23 (72) | 96 (75) | 0.746 |
 ACPA positivity, n (%) | 23 (72) | 101 (79) | 0.448 |
 SDAI | 22.1 (13.6–31.3) | 21.2 (14.6–29.3) | 0.320 |
 CDAI | 19 (12–28) | 20 (13–26) | 0.332 |
 RAPID3 | 3.3 (2.1–4.6) | 3.6 (2.7–5.2) | 0.128 |
 MMP-3 (ng/mL) | 184 (86–453) | 155 (86–358) | 0.440 |
Liver function | |||
 AST (U/L) | 18 (14–25) | 16 (14–21) | 0.630 |
 ALT (U/L) | 18 (12–29) | 15 (10–21) | 0.769 |
Radiographic status | |||
 Bony erosions, n (%) | 25 (78) | 96 (75) | 0.742 |
 JSN subscore | 5.5 (0–18.8) | 3.0 (1.0–9.8) | 0.078 |
 JE subscore | 6.0 (1.0–22.0) | 4.0 (0.3–10.0) | 0.009 |
 mTSS | 11.0 (1.3–36.3) | 8.0 (2.0–20.8) | 0.021 |
Previous medications, n (%) | |||
 Treatment-naïveb | 11 (34) | 55 (43) | 0.431 |
 GCs | 14 (44) | 48 (38) | 0.562 |
 MTX | 16 (50) | 49 (38) | 0.283 |
 LEF | 6 (19) | 34 (27) | 0.417 |
 SSZ | 4 (13) | 1 (1) | 0.005 |
 HCQ | 10 (31) | 12 (9) | 0.006 |
 CysA | 1 (3) | 5 (4) | 0.853 |
 Biologic agents | 1 (3) | 3 (2) | 0.821 |